Woodline Partners’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-189,057
| Closed | -$4.05M | – | 1062 |
|
|
2026
Q1 | $4.05M | Buy |
+189,057
| New | +$2.66M | 0.02% | 698 |
|
|
2025
Q3 | – | Sell |
-100,516
| Closed | -$653K | – | 923 |
|
|
2025
Q2 | $653K | Sell |
100,516
-112,638
| -53% | -$775K | ﹤0.01% | 834 |
|
|
2025
Q1 | $1.69M | Sell |
213,154
-585,771
| -73% | -$6.31M | 0.01% | 690 |
|
|
2024
Q4 | $10.1M | Buy |
798,925
+1,592
| +0.2% | +$22.2K | 0.07% | 341 |
|
|
2024
Q3 | $11.1M | Buy |
797,333
+89,802
| +13% | +$1.28M | 0.09% | 277 |
|
|
2024
Q2 | $9.75M | Buy |
707,531
+434,993
| +160% | +$6.36M | 0.09% | 250 |
|
|
2024
Q1 | $4.5M | Hold |
272,538
| – | – | 0.04% | 371 |
|
|
2023
Q4 | $3.98M | Hold |
272,538
| – | – | 0.04% | 337 |
|
|
2023
Q3 | $3.34M | Buy |
272,538
+61,538
| +29% | +$803K | 0.04% | 352 |
|
|
2023
Q2 | $2.52M | Buy |
211,000
+59,972
| +40% | +$783K | 0.03% | 401 |
|
|
2023
Q1 | $2.02M | Hold |
151,028
| – | – | 0.03% | 422 |
|
|
2022
Q4 | $3.25M | Buy |
+151,028
| New | +$3.1M | 0.04% | 385 |
|
|
2022
Q3 | – | Sell |
-150,176
| Closed | -$2.69M | – | 770 |
|
|
2022
Q2 | $2.69M | Buy |
+150,176
| New | +$1.55M | 0.04% | 386 |
|
Other funds holding DAWN
Woodline Partners's DAWN Position: Q2 2026 in Review
Woodline Partners sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 189,057 shares — an estimated $4.05M sold.
Woodline Partners first reported a position in DAWN in Q2 2022 and held it in 13 quarters. The position peaked at $11.1M in Q3 2024. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Woodline Partners reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Woodline Partners sold 189,057 Day One Biopharmaceuticals shares in Q2 2026, an estimated $4.05M.
- Woodline Partners first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 13 quarters.
- Woodline Partners's Day One Biopharmaceuticals position peaked at $11.1M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.